Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
TOKYO, Jul 9, 2020 – (JCN Newswire) – Eisai Co., Ltd. and Merck & Co.,…